Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-03-22FDA Approved: RISPERIDONE — Supplemental Application (Natco Pharma USA LLC)
FDA approved a supplemental application for risperidone from Natco Pharma USA LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2013-03-22Clinical Trial Update: Dental Status of Patients With Severe Mental Illness
Completed clinical trial evaluating dental health status in patients with severe mental illness, including schizophrenia, bipolar disorder, …
-
FDA approval · 2013-03-21FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for SAPHRIS (asenapine). The action approves an updated labeling related to a supplemen…
-
FDA label_change · 2013-03-18FDA Approved: OLANZAPINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for Olanzapine filed by Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2013-03-15Clinical Trial Update: Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia [Phase 4]
Phase 4 trial evaluating tolerability, safety and efficacy of flexibly dosed Paliperidone ER in schizophrenia. The results were posted in 20…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-03-15Clinical Trial Update: Switching to Iloperidone From Other Antipsychotics in Schizophrenia [Phase 4]
Phase 4 trial evaluating switching schizophrenia patients from other antipsychotics to iloperidone; results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-03-14Clinical Trial Update: Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics [Phase 4]
Phase 4 trial update reports appetite increases observed in schizophrenia patients treated with atypical antipsychotics.
-
CLINICAL_TRIALS trial_result · 2013-03-14Clinical Trial Update: Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics [Phase 4]
Phase 4 clinical trial evaluating whether melatonin mitigates metabolic adverse effects in patients treated with second generation antipsych…
-
CLINICAL_TRIALS research · 2013-03-14Clinical Trial Update: A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders [Phase 4]
Phase 4 multicenter study evaluating whether switching from risperidone or paliperidone to aripiprazole improves sexual dysfunction and hype…
-
CLINICAL_TRIALS research · 2013-03-08Clinical Trial Update: FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain
This completed multicenter cross-sectional epidemiological study examined the relationship between functioning status and sleep quality in o…
-
CLINICAL_TRIALS trial_result · 2013-03-06Clinical Trial Update: Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment [Phase 4]
Phase 4 trial evaluating rosiglitazone added to clozapine in schizophrenia patients with glucose metabolism impairment; the study was comple…
-
CLINICAL_TRIALS trial_result · 2013-03-05Clinical Trial Update: Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants [Phase 4]
Phase 4 safety and efficacy study of paliperidone extended-release in Thai participants with schizophrenia; results posted in 2013.
-
FDA approval · 2013-03-01FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for GEODON (ziprasidone mesylate) submitted by Viatris Specialty LLC.
-
FDA approval · 2013-03-01FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for GEODON (ziprasidone) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2013-03-01Clinical Trial Update: Huperzine for Cognitive and Functional Impairment in Schizophrenia [Phase 2]
A Phase 2 clinical trial evaluating huperzine for cognitive and functional impairment in schizophrenia has completed. The study was sponsore…
-
FDA approval · 2013-02-28FDA Approved: ABILIFY MAINTENA — Original Application (Otsuka America Pharmaceutical, Inc.)
The FDA approved ABILIFY MAINTENA (aripiprazole) through an Original Application (NDA202971) from Otsuka America Pharmaceutical, Inc.
-
CLINICAL_TRIALS trial_result · 2013-02-28Clinical Trial Update: Add-On Therapy to Risperidonein Schizophrenia [Phase 2, Phase 3]
Reports on a completed Phase 2/Phase 3 trial evaluating an add-on therapy to risperidone for schizophrenia.
-
FDA approval · 2013-02-26FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Risperdal Consta (risperidone) by Janssen, updating the labeling for the long-acting injecta…
-
CLINICAL_TRIALS trial_result · 2013-02-25Clinical Trial Update: Relative Effectiveness of Schizophrenia Therapy Study
This clinical trial studying the relative effectiveness of schizophrenia therapy has completed. The study also includes bipolar disorder amo…
-
CLINICAL_TRIALS trial_result · 2013-02-22Clinical Trial Update: Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
This update reports results from a youth-focused trial evaluating the effectiveness and tolerability of a second-generation antipsychotic ac…
-
CLINICAL_TRIALS research · 2013-02-20Clinical Trial Update: The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Clinical trial update assessing antiatherogenic properties of HDL in psychiatric patients, comparing those with and without antipsychotic th…
-
CLINICAL_TRIALS trial_result · 2013-02-18Clinical Trial Update: First Episode Schizophrenia and Cannabis-Related Disorder Study [NA]
Clinical trial update for a study on first-episode schizophrenia with cannabis-related and substance-related disorders; the study has comple…
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients [Phase 2]
A Phase 2 trial comparing talnetant, risperidone, and placebo in schizophrenic patients has completed.
-
CLINICAL_TRIALS research · 2013-02-15Clinical Trial Update: Coaching Intervention for Patients With Early Psychosis [NA]
This is a clinical trial update for a coaching intervention aimed at patients with early psychosis, specifically schizophrenia. The current …
-
CLINICAL_TRIALS trial_result · 2013-02-13Clinical Trial Update: Self-regulation Strategies to Improve Exercise Behavior Among Schizophrenic Patients [NA]
A completed clinical trial evaluating self-regulation strategies to improve exercise behavior in people with schizophrenia or schizoaffectiv…